REGEND007
Phase 1Cell therapy
REGEND007 is one of 69 biologic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Duragesic
CCephalon
Preclinical
Narcan
SScienture
Preclinical
Insulin Therapy
SanofiPreclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Curcumin
Merck & Co.Preclinical
Tetrahydrobiopterin
OOrphanetics Pharma Entwicklungs GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for REGEND007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- RRegend Therapeutics